KR101292348B1 - 피리딘 유도체 및 그의 정신병적 장애의 치료에 있어서의용도 - Google Patents
피리딘 유도체 및 그의 정신병적 장애의 치료에 있어서의용도 Download PDFInfo
- Publication number
- KR101292348B1 KR101292348B1 KR1020087008441A KR20087008441A KR101292348B1 KR 101292348 B1 KR101292348 B1 KR 101292348B1 KR 1020087008441 A KR1020087008441 A KR 1020087008441A KR 20087008441 A KR20087008441 A KR 20087008441A KR 101292348 B1 KR101292348 B1 KR 101292348B1
- Authority
- KR
- South Korea
- Prior art keywords
- group
- mmol
- alkyl
- solution
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(*)(C(CNC(C)(C)*1*)*1O)NC Chemical compound CC(*)(C(CNC(C)(C)*1*)*1O)NC 0.000 description 9
- ASMGFAOELMIEIG-UHFFFAOYSA-N CC(C)(C(N(C)c(c(-c(cc1)c(C)cc1F)c1)cnc1N(CC1)CC(C2)N1CCN2S(C)(=O)=O)=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 Chemical compound CC(C)(C(N(C)c(c(-c(cc1)c(C)cc1F)c1)cnc1N(CC1)CC(C2)N1CCN2S(C)(=O)=O)=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 ASMGFAOELMIEIG-UHFFFAOYSA-N 0.000 description 2
- PXYNCQRQUOOTSQ-QMMMGPOBSA-N C(C1)CN2[C@@H]1CCNCC2 Chemical compound C(C1)CN2[C@@H]1CCNCC2 PXYNCQRQUOOTSQ-QMMMGPOBSA-N 0.000 description 1
- FUEBLCGUMDEZGV-GEVKEYJPSA-N CC(C)(C(N(C)c(c(-c(cc1)c(C)cc1F)c1)cnc1N1CC([C@H](CC2)O)N2CC1)=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 Chemical compound CC(C)(C(N(C)c(c(-c(cc1)c(C)cc1F)c1)cnc1N1CC([C@H](CC2)O)N2CC1)=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 FUEBLCGUMDEZGV-GEVKEYJPSA-N 0.000 description 1
- ZEVGBKHBBMEDGX-JWQCQUIFSA-N CC(C)(C(N(C)c(c(-c(cc1)c(C)cc1F)c1)cnc1N1[C@@H](CO)CN(CCC2)[C@H]2C1)=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 Chemical compound CC(C)(C(N(C)c(c(-c(cc1)c(C)cc1F)c1)cnc1N1[C@@H](CO)CN(CCC2)[C@H]2C1)=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 ZEVGBKHBBMEDGX-JWQCQUIFSA-N 0.000 description 1
- YFMZALAUALIBHT-UHFFFAOYSA-N CC(C)(C(N(C)c(c(-c1ccccc1C)c1)cnc1N(CC1)CC2N1CCOC2)=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 Chemical compound CC(C)(C(N(C)c(c(-c1ccccc1C)c1)cnc1N(CC1)CC2N1CCOC2)=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 YFMZALAUALIBHT-UHFFFAOYSA-N 0.000 description 1
- PYCLKYVPYSJENJ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CC(CC2)N1S2(=O)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CC(CC2)N1S2(=O)=O)=O PYCLKYVPYSJENJ-UHFFFAOYSA-N 0.000 description 1
- VIPJHUZVKULMFE-GICMACPYSA-N CC(C)(C)[Si](C)(C)C[C@@H]1NCC(CN(CC2)C(C)=O)N2C1 Chemical compound CC(C)(C)[Si](C)(C)C[C@@H]1NCC(CN(CC2)C(C)=O)N2C1 VIPJHUZVKULMFE-GICMACPYSA-N 0.000 description 1
- DNLURHMRJYUSCL-UHFFFAOYSA-N CC(C)(C)[Si](C)(C)OCC(C(CCC1)N1CC1)N1c(cc1-c(cc2)c(C)cc2F)ncc1N(C)C(C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)=O Chemical compound CC(C)(C)[Si](C)(C)OCC(C(CCC1)N1CC1)N1c(cc1-c(cc2)c(C)cc2F)ncc1N(C)C(C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)=O DNLURHMRJYUSCL-UHFFFAOYSA-N 0.000 description 1
- CTMHPOMTRIFPIJ-UHFFFAOYSA-N CC(C1CCC1)N=C Chemical compound CC(C1CCC1)N=C CTMHPOMTRIFPIJ-UHFFFAOYSA-N 0.000 description 1
- VVYXIRKYWOEDRA-UHFFFAOYSA-N COC(C1NCCOC1)=O Chemical compound COC(C1NCCOC1)=O VVYXIRKYWOEDRA-UHFFFAOYSA-N 0.000 description 1
- AXBOKVWLPFNLNQ-QMMMGPOBSA-N COC(C[C@H]1N(CCN)CCC1)=O Chemical compound COC(C[C@H]1N(CCN)CCC1)=O AXBOKVWLPFNLNQ-QMMMGPOBSA-N 0.000 description 1
- RVAMHFNJLRUHBB-OAQYLSRUSA-N C[C@H](CN(CCN(C1)C(C)=O)[I]1C1)N1c(cc1-c(c(C)c2)ccc2F)ncc1N(C)C(C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)=O Chemical compound C[C@H](CN(CCN(C1)C(C)=O)[I]1C1)N1c(cc1-c(c(C)c2)ccc2F)ncc1N(C)C(C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)=O RVAMHFNJLRUHBB-OAQYLSRUSA-N 0.000 description 1
- CGWCNUYWSVMENN-VGOKPJQXSA-N C[C@H](CN1C(C2)COCC1)N2c(cc1-c(cc2)c(C)cc2F)ncc1N(C)C(C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)=O Chemical compound C[C@H](CN1C(C2)COCC1)N2c(cc1-c(cc2)c(C)cc2F)ncc1N(C)C(C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)=O CGWCNUYWSVMENN-VGOKPJQXSA-N 0.000 description 1
- UUUPNGVYOIXAAC-UHFFFAOYSA-N O=C1NCCN2C1CNCC2 Chemical compound O=C1NCCN2C1CNCC2 UUUPNGVYOIXAAC-UHFFFAOYSA-N 0.000 description 1
- UHRNMPVVZPATNT-UHFFFAOYSA-N OC(C(C=[O]CC1)N1P)O Chemical compound OC(C(C=[O]CC1)N1P)O UHRNMPVVZPATNT-UHFFFAOYSA-N 0.000 description 1
- ZEKMVSOHQJAAHS-UHFFFAOYSA-N OCC(C(N(CC1)C2CS1(=O)=O)=O)NC2=O Chemical compound OCC(C(N(CC1)C2CS1(=O)=O)=O)NC2=O ZEKMVSOHQJAAHS-UHFFFAOYSA-N 0.000 description 1
- SBYKKBMWYYUDMA-UHFFFAOYSA-N OCC(C1)NCC(C2)N1CC=[S]2(=O)=O Chemical compound OCC(C1)NCC(C2)N1CC=[S]2(=O)=O SBYKKBMWYYUDMA-UHFFFAOYSA-N 0.000 description 1
- PWLPKNYWXJOFKL-GVHYBUMESA-N OCC1N(CCC2)[C@H]2CNC1 Chemical compound OCC1N(CCC2)[C@H]2CNC1 PWLPKNYWXJOFKL-GVHYBUMESA-N 0.000 description 1
- SPZKTRAGSLOECK-GVHYBUMESA-N OC[C@@H]1NCC(CNCC2)N2C1 Chemical compound OC[C@@H]1NCC(CNCC2)N2C1 SPZKTRAGSLOECK-GVHYBUMESA-N 0.000 description 1
- HXQOJSREEGVBIN-GVHYBUMESA-N OC[C@@H]1NCC(CS(CC2)(=O)=O)N2C1 Chemical compound OC[C@@H]1NCC(CS(CC2)(=O)=O)N2C1 HXQOJSREEGVBIN-GVHYBUMESA-N 0.000 description 1
- CFLSJZYSROPVQC-LWOQYNTDSA-N OC[C@H](C(N(CC1)C2CS1(O)=O)=O)NC2=O Chemical compound OC[C@H](C(N(CC1)C2CS1(O)=O)=O)NC2=O CFLSJZYSROPVQC-LWOQYNTDSA-N 0.000 description 1
- YXMWPMAMMZJVEN-LWOQYNTDSA-N OC[C@H](C(N1C2CSCC1)=O)NC2=O Chemical compound OC[C@H](C(N1C2CSCC1)=O)NC2=O YXMWPMAMMZJVEN-LWOQYNTDSA-N 0.000 description 1
- UJIDITIXXKVIMJ-CHWSQXEVSA-N OC[C@H](C(N1[C@@H]2COCC1)=O)N(Cc1ccccc1)C2=O Chemical compound OC[C@H](C(N1[C@@H]2COCC1)=O)N(Cc1ccccc1)C2=O UJIDITIXXKVIMJ-CHWSQXEVSA-N 0.000 description 1
- JGLFLUHGPYMKTQ-MLCCFXAWSA-N OC[C@H]1N(Cc2ccccc2)CC(COCC2)N2C1 Chemical compound OC[C@H]1N(Cc2ccccc2)CC(COCC2)N2C1 JGLFLUHGPYMKTQ-MLCCFXAWSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0518472.6 | 2005-09-09 | ||
| GB0518472A GB0518472D0 (en) | 2005-09-09 | 2005-09-09 | Novel compounds |
| GB0611153A GB0611153D0 (en) | 2006-06-06 | 2006-06-06 | Novel compounds |
| GB0611153.8 | 2006-06-06 | ||
| PCT/EP2006/008845 WO2007028654A1 (en) | 2005-09-09 | 2006-09-07 | Pyridine derivatives and their use in the treatment of psychotic disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20080046232A KR20080046232A (ko) | 2008-05-26 |
| KR101292348B1 true KR101292348B1 (ko) | 2013-09-09 |
Family
ID=37546936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020087008441A Active KR101292348B1 (ko) | 2005-09-09 | 2006-09-07 | 피리딘 유도체 및 그의 정신병적 장애의 치료에 있어서의용도 |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US7683056B2 (https=) |
| EP (2) | EP1928886B1 (https=) |
| JP (1) | JP5121716B2 (https=) |
| KR (1) | KR101292348B1 (https=) |
| CN (1) | CN101305011B (https=) |
| AR (1) | AR058805A1 (https=) |
| AT (1) | ATE505472T1 (https=) |
| AU (1) | AU2006289281B2 (https=) |
| BR (1) | BRPI0615787B8 (https=) |
| CA (1) | CA2621564C (https=) |
| CR (1) | CR9847A (https=) |
| CY (1) | CY1111907T1 (https=) |
| DE (1) | DE602006021323D1 (https=) |
| DK (1) | DK1928886T3 (https=) |
| EA (1) | EA013909B1 (https=) |
| HR (1) | HRP20110457T1 (https=) |
| IL (1) | IL189578A (https=) |
| JO (1) | JO2722B1 (https=) |
| MA (1) | MA29780B1 (https=) |
| MY (1) | MY145713A (https=) |
| NO (1) | NO340921B1 (https=) |
| NZ (1) | NZ565983A (https=) |
| PE (1) | PE20070614A1 (https=) |
| PL (1) | PL1928886T3 (https=) |
| PT (1) | PT1928886E (https=) |
| SI (1) | SI1928886T1 (https=) |
| TW (1) | TWI378101B (https=) |
| WO (1) | WO2007028654A1 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007039123A2 (en) * | 2005-09-22 | 2007-04-12 | Smithkline Beecham Corporation | Combination therapy comprising an nk-3 antagonist and an antipsychotic agent |
| ATE472529T1 (de) * | 2005-10-10 | 2010-07-15 | Glaxo Group Ltd | Prolinamidderivate als natriumkanalmodulatoren |
| TW200730494A (en) * | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| CN102775396B (zh) | 2005-11-08 | 2014-10-08 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的杂环调控剂 |
| US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| WO2008090114A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| GEP20125379B (en) | 2007-05-03 | 2012-01-10 | Pfizer Ltd | 2 -pyridine carboxamide derivatives as sodium channel modulators |
| CN104447716A (zh) | 2007-05-09 | 2015-03-25 | 沃泰克斯药物股份有限公司 | Cftr调节剂 |
| MX365732B (es) | 2007-12-07 | 2019-06-12 | Vertex Pharma | Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos. |
| EP3683218B1 (en) | 2007-12-07 | 2024-09-18 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
| PL2098526T3 (pl) * | 2008-02-22 | 2014-06-30 | Neurotune Ag | Bicykliczne związki zawierające azot aktywne w stanach przewlekłego bólu |
| NZ720282A (en) | 2008-02-28 | 2017-12-22 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
| FR2928150A1 (fr) | 2008-02-29 | 2009-09-04 | Vetoquinol Sa Sa | Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens |
| WO2009119528A1 (ja) * | 2008-03-24 | 2009-10-01 | 武田薬品工業株式会社 | 複素環化合物 |
| GB0808747D0 (en) | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| EP2145891A1 (en) | 2008-07-09 | 2010-01-20 | Vetoquinol S.A. | 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials |
| GB0814340D0 (en) * | 2008-08-05 | 2008-09-10 | Smithkline Beecham Corp | Anhydrous crystol form fo a pyridine derivative |
| UY32826A (es) | 2009-08-04 | 2011-02-28 | Takeda Pharmaceutical | Compuestos heterocíclicos |
| CN102639536B (zh) * | 2009-08-27 | 2015-03-18 | 尼尔医疗有限公司 | 吡啶衍生物的无水晶型 |
| WO2011054773A1 (en) | 2009-11-03 | 2011-05-12 | Glaxosmithkline Llc | Novel lactam compounds |
| JP2013523833A (ja) | 2010-04-07 | 2013-06-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与 |
| EP2590953B1 (en) | 2010-07-09 | 2014-10-29 | Convergence Pharmaceuticals Limited | Tetrazole compounds as calcium channel blockers |
| US8648118B2 (en) | 2010-12-17 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Bicyclic ring system substituted amide functionalised phenols as medicaments |
| CN102617503B (zh) * | 2011-03-03 | 2014-05-07 | 上海常丰生物医药科技有限公司 | (s)-3-吗啉基羧酸的合成方法 |
| WO2013049164A1 (en) * | 2011-09-29 | 2013-04-04 | Abbvie Inc. | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS |
| WO2013049174A1 (en) | 2011-09-29 | 2013-04-04 | Abbvie Inc. | Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers |
| NZ727015A (en) | 2012-01-25 | 2017-12-22 | Vertex Pharma | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| WO2014093337A1 (en) | 2012-12-12 | 2014-06-19 | Abbvie, Inc. | Diazepine derivatives useful as calcium channel blockers in the treatment of pain |
| RU2673084C2 (ru) | 2013-11-08 | 2018-11-22 | Киссеи Фармасьютикал Ко., Лтд. | Производное карбоксиметилпиперидина |
| AU2014349010C1 (en) | 2013-11-12 | 2020-08-06 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases |
| TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
| WO2016021562A1 (ja) * | 2014-08-06 | 2016-02-11 | キッセイ薬品工業株式会社 | シアノチオフェン誘導体 |
| RU2691136C2 (ru) | 2014-11-18 | 2019-06-11 | Вертекс Фармасьютикалз Инкорпорейтед | Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии |
| ES2912881T3 (es) | 2014-12-23 | 2022-05-30 | Convergence Pharmaceuticals | Procedimiento para preparar derivados de alfa-carboxamida pirrolidina |
| EP3574907B1 (en) * | 2015-05-18 | 2023-08-23 | KaNDy Therapeutics Limited | A dual nk-1/nk-3 receptor antagonist for the treatment of sex-hormone-dependent diseases |
| CA3076823A1 (en) | 2017-10-05 | 2019-04-11 | Biogen Inc. | Process for preparing alpha-carboxamide pyrrolidine derivatives |
| JP7433252B2 (ja) | 2018-03-14 | 2024-02-19 | キャンディ・セラピューティクス・リミテッド | Ｎｋ－１／ｎｋ－３受容体二重アンタゴニストを含む新規な医薬製剤 |
| US11583538B2 (en) | 2019-04-08 | 2023-02-21 | Venenum Biodesign, LLC | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors |
| KR102950227B1 (ko) | 2019-11-15 | 2026-04-08 | 칸디 테라퓨틱스 리미티드 | Nt-814의 핵심 중간체인 6-클로로-4-(4-플루오로-2-메틸페닐)피리딘-3-아민의 새로운 화학적 제조 방법 |
| WO2021261969A1 (ko) * | 2020-06-26 | 2021-12-30 | 홀로스메딕 주식회사 | 신규한 화합물의 제조방법 |
| KR102682775B1 (ko) * | 2020-06-26 | 2024-07-08 | 홀로스메딕 주식회사 | 신규한 화합물의 제조방법 |
| WO2022075974A1 (en) * | 2020-10-06 | 2022-04-14 | Venenum Biodesign, LLC | Cyclic trex1 inhibitors |
| AU2022253448A1 (en) | 2021-04-05 | 2023-09-21 | The Board Of Trustees Of The Leland Stanford Junior University | Enantiomer selective action on neurotransmission |
| EP4431512A1 (en) | 2023-03-16 | 2024-09-18 | Bayer Consumer Care AG | Novel dual nk-1/nk-3 receptor antagonists |
| WO2025242584A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | A stable soft gelatin capsule formulation for elinzanetant |
| WO2025242585A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant |
| WO2025242583A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Novel formulation comprising elinzanetant in a solid dispersion |
| WO2025261856A1 (en) | 2024-06-18 | 2025-12-26 | Bayer Consumer Care Ag | Improved process for producing an elinzanetant precursor |
| US12533358B1 (en) | 2025-05-14 | 2026-01-27 | Bayer Consumer Care Ag | Methods of treatment with elinzanetant |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040086354A (ko) * | 2002-02-08 | 2004-10-08 | 글락소 그룹 리미티드 | 피페리딘 유도체 |
| WO2005002577A1 (en) * | 2003-07-03 | 2005-01-13 | F. Hoffmann-La Roche Ag | Dual nk1/nk3 antagonists for treating schizophrenia |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4921855A (en) | 1987-06-22 | 1990-05-01 | Fujisawa Pharmaceutical Co., Ltd. | New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same |
| US5166203A (en) | 1990-08-30 | 1992-11-24 | Kanebo, Ltd. | Quinolinecarboxylic acid derivatives, antibacterial agent containing the same |
| EP1486498A1 (en) | 1998-11-23 | 2004-12-15 | Pfizer Products Inc. | Process and intermediates for growth hormone secretagogues |
| EP1394150B1 (en) | 1999-02-24 | 2011-01-19 | F. Hoffmann-La Roche AG | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
| GT200000203A (es) | 1999-12-01 | 2002-05-24 | Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas. | |
| TWI259180B (en) | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
| GB0203022D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| TW200407324A (en) | 2002-05-17 | 2004-05-16 | Bristol Myers Squibb Co | Bicyclic modulators of androgen receptor function |
-
2006
- 2006-09-07 EP EP06777183A patent/EP1928886B1/en active Active
- 2006-09-07 DE DE602006021323T patent/DE602006021323D1/de active Active
- 2006-09-07 US US12/065,923 patent/US7683056B2/en active Active
- 2006-09-07 KR KR1020087008441A patent/KR101292348B1/ko active Active
- 2006-09-07 SI SI200631047T patent/SI1928886T1/sl unknown
- 2006-09-07 MY MYPI20064110A patent/MY145713A/en unknown
- 2006-09-07 CA CA2621564A patent/CA2621564C/en active Active
- 2006-09-07 AU AU2006289281A patent/AU2006289281B2/en active Active
- 2006-09-07 NZ NZ565983A patent/NZ565983A/en not_active IP Right Cessation
- 2006-09-07 TW TW095132989A patent/TWI378101B/zh active
- 2006-09-07 CN CN2006800418603A patent/CN101305011B/zh active Active
- 2006-09-07 PL PL06777183T patent/PL1928886T3/pl unknown
- 2006-09-07 EP EP10190918A patent/EP2336136A1/en not_active Withdrawn
- 2006-09-07 JO JO2006301A patent/JO2722B1/en active
- 2006-09-07 AR ARP060103894A patent/AR058805A1/es active IP Right Grant
- 2006-09-07 WO PCT/EP2006/008845 patent/WO2007028654A1/en not_active Ceased
- 2006-09-07 EA EA200800784A patent/EA013909B1/ru unknown
- 2006-09-07 HR HR20110457T patent/HRP20110457T1/hr unknown
- 2006-09-07 PE PE2006001077A patent/PE20070614A1/es not_active Application Discontinuation
- 2006-09-07 AT AT06777183T patent/ATE505472T1/de active
- 2006-09-07 PT PT06777183T patent/PT1928886E/pt unknown
- 2006-09-07 DK DK06777183.2T patent/DK1928886T3/da active
- 2006-09-07 BR BRPI0615787A patent/BRPI0615787B8/pt active IP Right Grant
- 2006-09-07 JP JP2008529564A patent/JP5121716B2/ja active Active
-
2008
- 2008-02-18 IL IL189578A patent/IL189578A/en active IP Right Grant
- 2008-03-17 MA MA30749A patent/MA29780B1/fr unknown
- 2008-03-28 CR CR9847A patent/CR9847A/es not_active Application Discontinuation
- 2008-04-07 NO NO20081728A patent/NO340921B1/no unknown
-
2009
- 2009-12-14 US US12/636,849 patent/US7919491B2/en active Active
-
2011
- 2011-02-23 US US13/032,740 patent/US8097618B2/en active Active
- 2011-07-04 CY CY20111100641T patent/CY1111907T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040086354A (ko) * | 2002-02-08 | 2004-10-08 | 글락소 그룹 리미티드 | 피페리딘 유도체 |
| WO2005002577A1 (en) * | 2003-07-03 | 2005-01-13 | F. Hoffmann-La Roche Ag | Dual nk1/nk3 antagonists for treating schizophrenia |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101292348B1 (ko) | 피리딘 유도체 및 그의 정신병적 장애의 치료에 있어서의용도 | |
| JP2009507801A5 (https=) | ||
| RU2722149C1 (ru) | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 | |
| US10414754B2 (en) | Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them | |
| WO2014078372A1 (en) | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors | |
| TWI444376B (zh) | 脯胺醯胺吡啶化合物、其藥學組成物及醫藥用途 | |
| KR20070057885A (ko) | 정신병성 장애의 치료를 위한 융합된 트리시클릭 유도체 | |
| EP3592740B1 (en) | Cyclic substituted imidazo[4,5-c]quinoline derivatives | |
| CN107344942B (zh) | 调节电压门控钠通道的化合物 | |
| MX2010011985A (es) | Espiro(piperidin-4,2'-pirrolidina)-1-(3,5-trifluorometilfenil)met ilcarboxamidas como antagonistas del receptor de taquicinina nk1. | |
| CN101084219A (zh) | 吡唑并[1,5－α]嘧啶基衍生物用作促肾上腺皮质激素释放因子(CRF)受体拮抗剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20080408 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20110907 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20121115 Patent event code: PE09021S01D |
|
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20130426 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20130520 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20130726 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20130726 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| FPAY | Annual fee payment |
Payment date: 20160705 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20160705 Start annual number: 4 End annual number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20170627 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20170627 Start annual number: 5 End annual number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20180702 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20180702 Start annual number: 6 End annual number: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20190701 Year of fee payment: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20190701 Start annual number: 7 End annual number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20200706 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20200706 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20210629 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210629 Start annual number: 9 End annual number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20220630 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20220630 Start annual number: 10 End annual number: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20230628 Start annual number: 11 End annual number: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240627 Start annual number: 12 End annual number: 12 |